PK of CC-93538 in Healthy Japanese and Caucasian Adults

Phase 1, randomised, open-label trial of cendakimab in eosinophilic esophagitis (EoE) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable concentration at Day 70, Area under the concentration-time curve from time zero extrapolated to infinity at Day 70 and 5 more. Started Oct 2019; status: completed.